Brussels-based UCB (Euronext: UCB) has announced that it has received marketing authorization from the European Commission for two new 320 mg device presentations of Bimzelx (bimekizumab).
These new options, a pre-filled syringe and pen, provide an alternative to the existing 160 mg injection, aiming to increase convenience for patients with a more streamlined dosing regimen.
The decision was widely expected, after a positive decision from a scientific panel earlier in the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze